• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Axonics® Announces Appointment of David M. Demski to Board of Directors

    12/14/20 8:00:00 AM ET
    $AXNX
    $GMED
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AXNX alert in real time by email

    IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021.

    Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a current market capitalization of over $5.9 billion. Mr. Demski has served as a member of the Globus board of directors since the inception of Globus in 2003. From 2003 until his appointment as CEO of Globus in 2017, Mr. Demski held various senior management positions at Globus, including chief financial officer, chief operating officer and president, Emerging Technologies. Mr. Demski received a B.S. in Business Administration from University of Michigan and an M.B.A. from Stanford Graduate School of Business.

    Juliet Tammenoms Bakker, managing director at venture capital firm Longitude Capital, has retired from the board of directors effective December 11, 2020. Erik Amble, chairman of Swiss-based NeoMed Management and a founding venture capital investor in Axonics, will be retiring from the board effective December 31, 2020.

    Mr. Demski said, "Axonics has done an outstanding job of executing on its business plan since the launch of its r-SNM product in the U.S. a year ago and I admire the company’s commitment to innovation for the benefit of patients, their families and clinicians. Axonics' technology advantage, distribution footprint and strong balance sheet provides the strategic foundation for significant future growth given the highly underpenetrated market for patients suffering from pelvic floor dysfunction. I am looking forward to serving on the board and working with the Axonics senior leadership team in the months and years ahead.”

    Raymond W. Cohen, CEO of Axonics, said, "We are thrilled to welcome Dave to our board of directors. He has extensive leadership experience in medical devices and a proven track record of successfully acquiring and scaling emerging growth businesses. We look forward to benefiting from Dave's strategic insight as Axonics continues to execute on its ambitious growth objectives.”

    Mr. Cohen continued, "We are grateful for the support and board service of Mr. Amble and Ms. Bakker, both of whom shared our vision of developing and commercializing a long-lived SNM device with the potential to change the lives of patients suffering from bladder and bowel dysfunction. On behalf of all Axonics stakeholders, I extend our sincere appreciation to Mr. Amble and Ms. Bakker."

    About Axonics Modulation Technologies, Inc.

    Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit www.axonics.com.

    Get the next $AXNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXNX
    $GMED

    CompanyDatePrice TargetRatingAnalyst
    Globus Medical Inc.
    $GMED
    5/27/2025Buy → Neutral
    BTIG Research
    Globus Medical Inc.
    $GMED
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    Globus Medical Inc.
    $GMED
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    Globus Medical Inc.
    $GMED
    8/7/2024$60.00 → $78.00Equal Weight → Overweight
    Wells Fargo
    Globus Medical Inc.
    $GMED
    5/20/2024$60.00 → $80.00Neutral → Overweight
    Piper Sandler
    Globus Medical Inc.
    $GMED
    3/18/2024$60.00Neutral → Buy
    BTIG Research
    Axonics Inc.
    $AXNX
    1/9/2024Outperform → Peer Perform
    Wolfe Research
    Globus Medical Inc.
    $GMED
    10/20/2023$75.00Buy
    ROTH MKM
    More analyst ratings

    $AXNX
    $GMED
    SEC Filings

    See more
    • SEC Form SD filed by Globus Medical Inc.

      SD - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/29/25 4:15:11 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/15/25 4:41:35 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Globus Medical Inc.

      10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 5:19:05 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $AXNX
    $GMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/14/24 4:08:54 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 5:06:16 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/13/24 4:59:03 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AXNX
    $GMED
    Financials

    Live finance-specific insights

    See more
    • Globus Medical Announces $500 Million Share Repurchase Program

      AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company's outstanding common stock. "We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation," said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. "Given our strong track record of growth and profitability, we are confident in the long-term strength of our business. This repurchase authorization reflects that confidence and reinforc

      5/15/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care

    $AXNX
    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Globus Medical downgraded by BTIG Research

      BTIG Research downgraded Globus Medical from Buy to Neutral

      5/27/25 9:07:37 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00

      1/10/25 8:55:48 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously

      12/2/24 6:57:12 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $AXNX
    $GMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

      Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer

      7/25/24 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

      BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

      12/27/23 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Davidar David D

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:18:17 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Deford John A

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:15:42 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Douglas Robert Andrew

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:13:33 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care